Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network

During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Leukemia
Glavni autori: Ludwig, Heinz, Delforge, Michel, Facon, Thierry, Einsele, Hermann, Gay, Francesca, Moreau, Philippe, Avet-Loiseau, Hervé, Boccadoro, Mario, Hajek, Roman, Mohty, Mohamad, Cavo, Michele, Dimopoulos, Meletios A, San-Miguel, Jesús F, Terpos, Evangelos, Zweegman, Sonja, Garderet, Laurent, Mateos, María-Victoria, Cook, Gordon, Leleu, Xavier, Goldschmidt, Hartmut, Jackson, Graham, Kaiser, Martin, Weisel, Katja, van de Donk, Niels W. C. J., Waage, Anders, Beksac, Meral, Mellqvist, Ulf H., Engelhardt, Monika, Caers, Jo, Driessen, Christoph, Bladé, Joan, Sonneveld, Pieter
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2018
Teme:
Review Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6035147/
https://ncbi.nlm.nih.gov/pubmed/29720735
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-018-0040-1
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items